Compare Lam Research Corporation (LRCX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs 10X Genomics Inc — how do they compare? Lam Research Corporation trades at $319 (market cap $401.19B), while 10X Genomics Inc trades at $81 (market cap $10.07B). The key difference: Lam Research Corporation is far larger — about 39.8× 10X Genomics Inc's market cap, and Lam Research Corporation pays a 0.41% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 60 Days and 10X Genomics Inc for 91 Days on average.
| LRCX | TXG | |
|---|---|---|
Market Cap | $401.19B | $10.07B |
Volume | 8,960,892 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $433.33 | $97.74 |
52-Week Low | $131.37 | $11.48 |
Typical Hold Time | 60 Days | 91 Days |
Enterprise Value | $399.35B | $9.59B |
Dividend Yield | 0.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $318.84, down 3.24% on the day, with strong fundamentals including 29.06% net margin and consistent earnings beats. Technical indicators show a bearish short-term signal despite bullish moving averages, with key support at $314 and resistance at $329. Recent news highlights LRCX's positioning in AI-driven semiconductor equipment demand, with revenue growth accelerating to $18.44B in 2025.
Outlook remains positive with 78% analyst buy ratings and $375.68 consensus price target, representing 18% upside. Key risks include semiconductor cycle volatility and execution challenges in maintaining mid-40% operating margins. The stock offers growth exposure to AI infrastructure spending but faces competitive pressures in chip equipment markets.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
